If we can align our regulatory processes to those of countries like Canada so that generic drugs can be approved very quickly after the expiry of…
In Conversation
At the beginning of my career, over 20 years ago, there were no market access issues, as the reimbursement and pricing system was set up around…
[Infrastructure, education, and healthcare] are the key to better serving the Romanian citizens and making the country more attractive
In terms of pricing, the average biosimilar coming to market is 30 to 38 percent lower in price than the originator ... Biosimilars currently available in…
One of the things that we have to understand as a party and as a society is that it is not easy for the government to…
Stakeholders are aware that medical devices complement medicines and we are in constant discussion with the government, regulators, and payers to communicate what medical technologies are…
We were the first group to start a country-wide expansion, from Saudi Arabia we expanded to the region and we have the vision to be present…
We are passing through difficult times for generics companies in Romania
Despite the lack of visibility on approval timelines, we are already running clinical trials locally, because we are convinced about the high value clinical trials can…
The next step of success is to bring innovation to such a level that our customers say they cannot imagine a world without IQVIA!
As a multicultural company, we believe in the future growth of Belgium’s innovative biotechnology sector. It is absolutely a country which should be observed carefully by…
Without any doubt, my biggest achievement at EastHORN is building a strong team that I can always rely on. Once you have found the perfect team,…
